Research programme: heart surgery therapeutics - Phylogica/Baker IDI

Drug Profile

Research programme: heart surgery therapeutics - Phylogica/Baker IDI

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Baker Heart Research Institute; Phylogica
  • Developer Baker IDI; Phylogica
  • Class Peptide fragments
  • Mechanism of Action Cell death inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Ischaemic heart disorders

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for research development in Ischaemic-heart-disorders in Australia (Parenteral)
  • 19 Apr 2010 Early research is ongoing in Australia
  • 26 Jul 2006 Early research in Ischaemic heart disorders in Australia (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top